Previously, our group validated this antibody on patient-derived glioma stem-like cells and on surgical specimens of glioma with mutant IDH1/2, in which we showed a co-staining of the tumor cells with anti-IDH1/2 and anti-CRMP5 antibodies [21,22]. This evidence concerns the gene DPYSL5 and neoplasm.